NCT05704920Recruiting
Integrating Artificial Intelligence Into Lung Cancer Screening.
A Randomized Controlled Study of Including a Deep Learning-based Analysis of Chest Computed Tomography as an Aid to Decision Making of Multidisciplinary Team Meetings for Lung Cancer Screening in Eligible Patients
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
Lung cancer (LC) screening using low-dose chest CT (LDCT) has already proven its efficacy. The mortality reduction associated with LC screening is around 20%, much higher than the reduction in mortality associated with screening for breast, colon or prostate cancers. Implementing lung cancer screening on a large scale faces two main obstacles: 1. The lack of thoracic radiologists and LDCT necessary for the eligible population (between 1.6 and 2.2 million people in France); 2. The high frequency of false positive screenings: in the NLST trial, more than 20% of the subjects screened were found to have at least one nodule of an indeterminate lung nodule (ILN) whereas less than 3% of ILNs are actually LC. The gold standard for determining on the benign or malignant nature of a nodule is definitive histology. Otherwise, the evolution of the nodule on serial thoracic imaging is a good alternative. The period of indeterminacy of a nodule can be as long as 24 months in many cases, which can be a source of prolonged and sometimes unjustified anxiety for screening candidates. The purpose of this randomized controlled study that focuses on LC screening in patients aged 50 to 80 years, who smoked more than 20 packs/ year or stopped smoking less than 15 years ago. Its objective is to determine whether assisting multidisciplinary team (MDT) meetings with an AI-based analysis of screening LDCT accelerates the definitive classification of nodules into malignant or benign.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 2722 (estimated)
- First submitted
- 19 Jan 2023
- Start date
- 8 Apr 2024
- Primary completion date
- 1 Mar 2029
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Diseases
- Lung cancer
- NCT number
- NCT05704920
What you commit to
- Study type: Interventional
- Planned participants: 2722
- From 8 Apr 2024 to the primary completion date, 1 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- health problem limiting ability or willingness to undergo lung surgery
Other illness
- clinical signs suggestive of cancer
- vulnerable people: adults under guardianship, adults under curatorship medical and/or psychiatric problems of sufficient severity to limit full adherence to the study or expose patients to excessive risk
Other
- recent chest scan (\<1 year) for another cause
- radiological abnormality requiring follow-up or additional investigations
- health problem significantly limiting life expectancy from the clinician's point of view
- Patients with active neoplasia, except basal cell carcinoma of the skin.
Who the study is looking for
- Age between 50 and 80 years old
- active smoker or ex-smoker who quit smoking less than 15 years ago
- smoking history of at least 20 pack-years
- signature of the informed consent
- affiliation to French social security
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Nice - Hôpital de Pasteur Coordinator of this site? Confirm its status | Nice | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.